APA (7th ed.) Citation

Schüle-Freyer, R., Graessner, H., Aartsma-Rus, A., van Roon-Mom, W. M. C., & Synofzik, M. (2025). Tailored antisense oligonucleotides for ultrarare CNS diseases: An experience-based best practice framework for individual patient evaluation. Molecular therapy. Nucleic Acids, 36(3), . https://doi.org/10.1016/j.omtn.2025.102615

Chicago Style (17th ed.) Citation

Schüle-Freyer, Rebecca, Holm Graessner, Annemieke Aartsma-Rus, Willeke M. C. van Roon-Mom, and Matthis Synofzik. "Tailored Antisense Oligonucleotides for Ultrarare CNS Diseases: An Experience-based Best Practice Framework for Individual Patient Evaluation." Molecular Therapy. Nucleic Acids 36, no. 3 (2025). https://doi.org/10.1016/j.omtn.2025.102615.

MLA (9th ed.) Citation

Schüle-Freyer, Rebecca, et al. "Tailored Antisense Oligonucleotides for Ultrarare CNS Diseases: An Experience-based Best Practice Framework for Individual Patient Evaluation." Molecular Therapy. Nucleic Acids, vol. 36, no. 3, 2025, https://doi.org/10.1016/j.omtn.2025.102615.